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Purpose: Visual field (VF) examination by standard automated perimetry (SAP) is an
important method of clinical assessment. However, the complexity of the test, and its
use of bulky, expensive equipment makes it impractical for case-finding. We propose
and evaluate a new approach to paracentral VF assessment that combines an
inexpensive eye-tracker with a portable tablet computer (‘‘Eyecatcher’’).
Methods: Twenty-four eyes from 12 glaucoma patients, and 12 eyes from six age-
similar controls were examined. Participants were tested monocularly (once per eye),
with both the novel Eyecatcher test and traditional SAP (HFA SITA standard 24-2). For
Eyecatcher, the participant’s task was to simply to look at a sequence of fixed-
luminance dots, presented relative to the current point of fixation. Start and end
fixations were used to determine locations where stimuli were seen/unseen, and to
build a continuous map of sensitivity loss across a VF of approximately 208.
Results: Eyecatcher was able to clearly separate patients from controls, and the
results were consistent with those from traditional SAP. In particular, mean Eyecatcher
scores were strongly correlated with mean deviation scores (r2 ¼ 0.64, P , 0.001), and
there was good concordance between corresponding VF locations (~84%).
Participants reported that Eyecatcher was more enjoyable, easier to perform, and
less tiring than SAP (all P , 0.001).
Conclusions: Portable perimetry using an inexpensive eye-tracker and a tablet
computer is feasible, although possible means of improvement are suggested.
Translational Relevance: Such a test could have significant utility as a case finding
device.
Introduction
Measuring visual field loss is a key component of
an eye examination. It is a particular cornerstone of
glaucoma assessments, where optic nerve damage
typically results in asymptomatic visual field loss that
can only be detected by perimetric examination.1
When deployed appropriately, standard automated
perimetry (SAP) can be used successfully to manage
visual field loss and evaluate treatment efficacy.2
However, current SAP devices lack portability and
are expensive. This makes them impractical in some
settings, and restricts in particular their use in
glaucoma case finding. Furthermore, many people
find visual field examination by SAP challenging or
uncomfortable. Indeed, even experienced test takers
describe feelings of anxiety when faced with a visual
field examination.3 Sometimes it is best to describe a
problem in lay terms: pressing a button to detect spots
of light in a large white bowl whilst trying to keep
your eye and head perfectly still is simply an
unnatural task.
A portable, inexpensive, and user-friendly device
would allow for more effective visual field screening,
particularly in resource-poor or hard to reach
communities. This in turn could help to improve
detection rates for diseases such as glaucoma (which
are currently poor1,4), and may lead to fewer patients
presenting to hospital eye service with already
advanced visual field loss.5–7
One way to make perimetry easier and more
comfortable is to use eye- and head-tracking technol-
ogy. If the position of eye and head can be monitored
accurately, then stimuli can be presented relative to
1 TVST j 2019 j Vol. 8 j No. 1 j Article 17
This work is licensed under a Creative Commons Attribution 4.0 International License.Downloaded from tvst.arvojournals.org on 02/11/2019
the current point of fixation, irrespective of where the
patient is looking. Furthermore, stimuli can be scaled
to be a constant size on the retina, irrespective of
viewing distance. This removes completely the need
for chin rests or fixation crosses. In addition, the use
of eye-tracking further obviates the need for any
button-pressing or detailed task instructions, since
eye-movements toward transient stimuli are largely
reflexive, and occur robustly even in infants8–10 and
individuals with cognitive impairments.11 According-
ly, a number of groups have recently developed eye-
tracking based perimetry,12–17 capable, for example,
of discriminating between healthy and glaucomatous
eyes.14 However, to date these systems still suffer from
many of the same limitations regarding portability
and cost.
One way to make perimetry more portable and
inexpensive is to exploit modern tablet computers.18,19
Thus, a number of tablet-based apps have recently
been developed for measuring visual field loss,20–26 as
well as other aspects of visual function such as visual
acuity (VA),27–30 contrast sensitivity (CS),31–35 foveal
defects,36 and stereopsis.37 The hope is that these tests
could be used as an alternative to traditional, more
expensive tests, or could allow patients to be
monitored more regularly from the comfort of their
own homes. This could bring considerable benefits in
terms of reduced healthcare costs, an improved
patient experience, and the ability to detect high-risk
individuals more quickly than traditional (i.e., annual
or biannual) monitoring regimens.20 However, the
lack of eye- and head-tracking is an acknowledged
limitation of current tablet perimeters.22 To ensure
that stimuli are accurately localized on the retina, the
patient is required to keep their head steady and their
fixation constant: tasks that many patients find
difficult and unnatural.38 And, unlike SAP, a
technician is not on hand to ensure compliance.
These factors are likely to severely limit the accuracy
and reliability of any test results.
The current study represents a first attempt to
bring together the best of these two strands of
research, by combining an ordinary tablet computer
with an inexpensive ‘‘clip-on’’ eye-tracker. The
resultant test, which we call ‘‘Eyecatcher,’’ is not
intended as a like-for-like replacement for SAP, but is
instead proposed as a portable, inexpensive, rapid,
and easy-to-use case finding device. Unlike SAP, eye-
movements are permitted, and no button-pressing or
head restraint is required: the participant is required
only to look at the tablet screen and follow a dot with
their eye. Also unlike standard SAP, stimuli were of
fixed luminance (suprathreshold perimetry), as the
test was only intended to detect clinically meaningful
defects.
In this report, we present Eyecatcher and compare
it with SAP in people with glaucoma and visually
healthy peers. Specifically, we examined whether the
two tests gave concordant results, and evaluated their
relative speed, completion rates, and levels of user-
satisfaction. We also identify limitations of the
approach and this current implementation.
Methods
Participants
Participants were 12 patients with diagnosed
glaucoma (median age, 70 years), and six age-similar
controls (median age, 76 years; see the Table). Patients
were recruited from clinics at Moorfields Eye Hospital
NHS Foundation Trust, London. All patients had an
established (4þ years) clinical diagnosis of chronic
open-angle glaucoma in both eyes, and were being
treated. A deliberate attempt was made to recruit a
sample of patients with a wide range of disease severity
according to visual field loss (see the Table). Patients
were purposely not recruited if they had any ocular
disease other than glaucoma (except for an uncompli-
cated lens replacement cataract surgery). Age-similar
controls were recruited from the City, University of
London Optometry Clinic; this is a primary care center
where people routinely receive a full eye examination,
which includes measurement of VA, refraction, binoc-
ular vision assessment, pupil reactions, slit-lamp
assessment of the anterior eye, measurement of
intraocular pressure, visual field assessment and
indirect ophthalmoscopy of the macula, optic nerve
head, and peripheral retina. All participants had taken
part in studies in our research laboratory before.
Institutional Ethics Committee approval was obtained,
and the research adhered to the tenets of the
Declaration of Helsinki. Written informed consent
was obtained prior to all examinations.
Vision Testing
Standard visual fields were measured in both eyes
using the Humphrey Field Analyzer (HFA; Carl Zeiss
Meditec, CA) with the central standard 24-2 Swedish
Interactive Testing Algorithm. The Glaucoma Hemi-
field Test (GHT) was ‘‘outside normal limits’’ for all
eyes in all patients and ‘‘within normal limits’’ for all
eyes in all controls.39 If any of the visual fields were
flagged by the HFA output as ‘‘unreliable’’ (as
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assessed by false positives, false negatives, or poor
fixation measures), then the test was repeated. HFA
mean deviation (MD) values were used as a measure
of overall glaucomatous disease severity in the patient
group.
Corrected monocular VA was measured using an
Early Treatment Diabetic Retinopathy Study
(ETDRS) chart. CS was measured in log units with
a Pelli-Robson chart. The Oculus C-Quant straylight
meter (Oculus GmbH, Wetzlar, Germany) was used
to measure abnormal light scattering in the eye media,
in order to eliminate significant media opacity and
other lens type artefacts as confounding ocular
conditions; all participants were required to be within
‘‘normal limits’’ for this test.
The Novel Test (Eyecatcher)
Apparatus
The equipment for the Eyecatcher visual field test is
shown in Figure 1A. Stimuli were displayed on a
Microsoft Surface Pro 3 (Microsoft, Redmond, WA): a
portable ‘‘tablet computer,’’ containing a screen
measuring 25.43 16.9 cm (28.58 3 19.28 at the viewing
distance of ~50 cm). Eye movements were recorded
monocularly at 50 Hz using a Tobii EyeX eye-tracker
(Tobii Technology, Stockholm, Sweden): a low-cost
(~$100), near-infrared, remote eye-tracker, with a
precision of , 0.68.40 Participants were sat approxi-
mately 50 cm from the screen. However, no chin rest
was used, and participants were free to move their
head. A constant stimulus size on the retina was
maintained by scaling the screen-size of the stimulus
trial-by-trial, based on the participant’s current viewing
distance (as measured by the EyeX eye-tracker, which
also contains integrated head-tracking). The test was
programmed in C# and R,41 using custom code.
Task
Participants viewed the tablet monocularly (fellow
eye patched), and were asked simply to ‘‘follow the
dot.’’ Unlike SAP, they were not required to maintain
fixation or press a button, since the eye-tracker was
used to position stimuli and assess eye-movement
responses (see below). Each eye was tested separately,
in random order.
Stimuli
Stimuli were white Goldmann III (0.438) circular
spots, presented at a fixed intensity of 300 cd/m2
(equivalent to a ~10 dB target in the HFA). Stimuli
were presented against a white 31 cd/m2 background.
The background was brighter than the HFA back-
Table. Participant ages and clinical screeningmeasures.
VA was assessed using an ETDRS chart, and is reported in
logMAR (BL, Bare Light perception only). Visual fields
were assessed using SAP (24-2 SITA standard) and is
reported in MD (dB)—see also Figure 3 for pointwise
data. CS was measured using Pelli Robson charts, and is
reported in logCS.
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ground (10 cd/m2) as the eye-tracker was observed to
perform poorly under very low illumination. Lumi-
nance calibration was performed using a Minolta LS-
110 spot photometer (Minolta Camera Co., Osaka,
Japan).
Scoring Hits and Misses
A typical trial sequence is shown in Figure 1C. At
the start of each trial, a stimulus was presented at a
random location on an adapted 24-2 grid (see below).
If, within 1500 ms of trial onset, the participant’s gaze
fell within 2.98 of the stimulus, then the trial was scored
as a Hit (target seen). Otherwise, the trial was scored as
a Miss (target unseen). If a trial was scored a Hit, then
the current stimulus remained visible on the screen
until the next point was fixated, but any previous
points were hidden. From the user’s perspective, they
effectively ‘‘chased’’ a dot around the screen. If a trial
was scored a Miss, then the current stimulus disap-
peared after 1500 ms; however, the last seen target
remained visible (see Fig. 1C). The previous target was
left visible as an optional ‘‘anchor,’’ to minimize
unnecessary eye movements. However, this was not
an obligatory fixation target, and participants were free
to move their gaze if desired.
Measurement Grid
The underlying measurement grid is shown in
Figure 1B. It consisted primarily of points from the
standard 24-2 that could be fit within the view angle
of the screen, along with four additional points at
h6108, 6108i. The four most central points from the
24-2 grid were omitted, as the spatial imprecision of
the eye-tracker meant that measurements at these
locations would be unreliable. The test attempted to
test each location four times. Note, however, that
because participants were free to move their eyes, and
since stimuli were presented for relatively long
duration (1500 ms), it was possible for participants
to ‘‘cheat’’ by searching for the target. We developed a
novel solution to account for this, as detailed in
Figure 2. However, this resulted in the underlying test
grid becoming irregular (see Fig. 2E).
Outcome Measures
The primary outcome measure was a map of hit
rates, which can be interpreted as ‘‘probability of
seeing’’ values. This map was constructed after the test
was complete by using a technique known as Kriging
to interpolate between responses across individual
trials/locations42 (see Fig. 2). A summary measure of
this map was also generated by mean-averaging the
expected hit rate value at each of the discrete 24-2
locations present within the Kriging surface. The
resultant metric, ‘‘Mean Hit Rate,’’ can be understood
as the average amount of ‘‘greenness’’ in the plot, and
is potentially comparable to HFA’s MD metric.
Analysis: Comparison With HFA
We validated Eyecatcher against the HFA (the
Reference Standard) in three ways. First, we com-
pared visually the HFA grayscales against the Eye-
catcher maps. Second, we computed pointwise
concordance between the tests for defects at each of
the HFA locations contained within the Eyecatcher
surface. A location was defined as concordant if both
‘‘SensitivityHFA , 25 dB’’ and ‘‘Hit RateEyecatcher ,
0.5’’ (or the inverse), where 25 dB was an arbitrary
threshold, but one that we believed most clinicians
would regard as clinically significant. We then
computed the percentage of concordant points for
each eye. Note that the two tests do not measure the
same thing: Eyecatcher measures hit rate (frequency
of seeing) for a fixed threshold stimulus, whereas the
HFA measures thresholds (just noticeable differenc-
es). There are therefore no directly equivalent cutoff
Figure 1. Eyecatcher Methods. (A) The key test equipment,
comprised of a Microsoft Surface Pro 3 tablet (viewing at 50 cm),
and a Tobii EyeX eye-tracker, which was attached to the bottom of
the screen by magnets. (B) The underlying test grid, in retinal
coordinates (though note that actual locations could deviate from
the underlying grid, as shown in Fig. 2). (C) An example trial
sequence, in which a stimuli are presented relative to the current
point of fixation, and the eye-tracker determines whether the
participant moved their eyes toward the target. See body text for
details.
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points for the two tests. However, the present findings
were qualitatively unchanged when values other than
, 25 dB and, 0.5 were used. Third, we estimated the
degree of correlation between the summary measures
of visual field loss from Eyecatcher (Mean Hit Rate)
and HFA (MD).
Analysis: Usability
Participants were given a short ‘‘usability’’ ques-
tionnaire, in which they were asked to assess both the
HFA and Eyecatcher along five dimensions. Each
question consisted of a statement (‘‘I found the test. . .
enjoyable, easy, tiring, hard to concentrate on,’’ and
‘‘I understood what was required’’) to which partic-
ipants were asked to rate their agreement based on a
five-point Likert scale.
Results
Test results for all individuals are shown in Figure
3. By inspection, it can be seen that there was good
separation between patients (ID 7–18) and healthy
peers (ID 1–6), and also between those eyes with mild
and severe impairment (e.g., see ID 7, 11, and 13).
These differences were confirmed statistically. Thus,
there were significant differences in mean hit rate
(‘‘amount of greenness’’) between the eyes of patients
and controls (Between subjects t-test; P , 0.001) and
also between patients’ eyes with moderate (MD , 12
dB) and severe (MD . 12 dB) field loss (P , 0.001).
Within a single eye, Eyecatcher was also able to
localize scotomas with reasonable spatial precision.
Note, for example, the spared central vision in IDs 9
and 11, and the lower hemifield loss in IDs 10 and 14.
In some cases, however, Eyecatcher did appear to
overestimate the spread of visual field loss (e.g., IDs
13, 16, and 18).
Statistically, concordance between visual field
defects on Eyecatcher field maps and HFA grayscales
was generally good. Median (quartiles) percentage of
concordant points was 83% (59%, 91%) in the 22
patient eyes, and 97% (92%, 97%) in the 12 eyes from
visually healthy peers. As shown in Figure 4, there
was also a good correlation between summary
measures of visual field loss from Eyecatcher and
Figure 2. Computing performance using Eyecatcher. (A) Initially Eyecatcher attempted to present four stimuli at each of the 44 test
locations in the underlying measurement grid (Fig. 1B). For each trial, the participant’s response was scored as either a hit (green dots), or
a Miss (red dots – NB: the location of each dot has been jittered slightly for visibility). (B, C) To correct for eye movements, after each trial
(and irrespective of whether it was scored as a Hit or a Miss), the software searched back 200 ms, and used the participant’s gaze location
at this prior time point to replace the intended stimulus location (orange dots) with its true location (green/red dots). (D) The empirical test
grid, after post hoc correction (same data as [A]). Due to the correction for eye movements, the precise shape and extent of this map is
liable to differ on every test. (E) Finally, Kriging42 was used to interpolate the corrected data to provide a continuous heatmap indicating
the Probability of Seeing at each location (red: highly unlikely; green: highly likely). Kriging was performed in R, using the Fields package.43
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Figure 3. Concordance in pointwise sensitivity (Eyecatcher versus HFA). Results are shown for each individual eye, with the HFA
Greyscale on the left, and the corresponding Eyecatcher Kriging surface on the right. If concordance was good, then black areas in the
HFA Greyscale should appear as red areas on the Eyecatcher Kriging surface. Numbers indicate the percentage of concordant values at
each 24-2 location present in both maps. Markers correspond to the list of individuals in the Table. Individuals 1–6 (gray rectangle)
indicate healthy controls.
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HFA MD in patient eyes (Pearson Correlation: P ,
0.001, r2 ¼ 0.64).
In terms of completion rates, all participants
completed the HFA exam in both eyes (100%
completion). However, two patients were only able
to complete Eyecatcher in one eye (92% completion).
In one case (ID 8/R), the vision loss was so severe that
the patient was unable see to complete the initial eye-
tracker calibration. In the other case (ID 17/R) the
eye was highly myopic (12.50/þ2.00 3 90) and the
eye-tracker was unable to track it reliably.
Eyecatcher was faster to complete than the HFA.
In patients, mean (CI95%) test durations for Eye-
catcher were 5.1 minutes (4.6, 5.5), versus 6.9 minutes
(6.5, 7.5) for HFA (Pairwise t-test: P , 0.001). In
healthy peers, test durations were 3.4 minutes (3.2,
3.5) for Eyecatcher, versus 4.8 minutes (4.6, 5.2) for
HFA (Pairwise t-test: P , 0.001).
As shown in Figures 5, participants rated Eye-
catcher more enjoyable, easier to perform, less tiring,
and less hard to concentrate on than SAP (all P ,
0.001). There was no difference in task-comprehen-
sion (P ¼ 0.495), which was high for both tests—
though it may be worth noting that participants
already had previous experience of HFA testing.
Discussion
Current SAP devices are not well-suited for
glaucoma case-finding, due to being bulky, expensive,
and often challenging to administer.3 The present
study proposes and evaluates a novel alternative
(‘‘Eyecatcher’’): a portable, suprathreshold eye-move-
ment perimeter, which uses an inexpensive ‘‘clip-on’’
eye-tracker to detect eye movements toward succes-
sive targets (Goldmann III white lights). Unlike
traditional SAP—or alternatives such as Frequency
Doubling Technology,44–46 Flicker Perimetry,47 or
Rarebit Perimetry48–50—this new approach requires
minimal task-instructions, and does not require the
participant to press a button or maintain fixation on a
central marker. And unlike other eye-movement
perimeters,12–17 Eyecatcher is intended primarily as
a case-finding tool, and can be deployed using only a
portable tablet-computer and low cost eye-tracking
device (~$100). This makes it potentially well-suited
to rapidly identifying cases of suspected visual field
loss, even in traditionally difficult to test populations.
Overall, the results showed that the approach is
feasible, and that Eyecatcher shows promise as a
rapid case-identification tool for visual field loss.
Most individuals were able to complete the test with
minimal difficulty, and the results showed good
concordance with values derived from SAP (HFA).
Our participants also reported a clear preference for
Eyecatcher over SAP and this is particularly note-
worthy. We consider each of these findings in turn,
and discuss important caveats.
Figure 4. Agreement in overall sensitivity (Eyecatcher Mean Hit-
Rate versus HFA MD value). Each data point represents a single eye
from a patient (N ¼ 22). The solid line shows the best fitting
geometric-mean regression slope (i.e., ‘‘error-in-both-axes
regression’’).
Figure 5. Group-mean [6 95% confidence interval] usability
scores for the new test (Eyecatcher: blue) versus traditional
perimetry (HFA: red): 1, strongly disagree; 5, strongly agree.
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In terms of completion rates, all participants were
able to perform the Eyecatcher test in at least one eye.
However, two eyes with severe loss could not be
tested: one because their vision was too poor to see
the screen (ID 8/R), and the other because the eye-
tracker was unable to track their eye through the
patient’s 12.5 diopter lenses (ID 17/R). Failures of
this kind are not a substantial concern for our
proposed case-finding device, since individuals with
such severe vision loss would be expected to be
receiving care already. However, the fact that eye-
movement perimetry is not always possible would be
important to bear in mind if considering it as a like-
for-like replacement for current SAP devices.
There was good consistency between the results of
Eyecatcher and HFA. Although the two tests are not
equivalent (Eyecatcher measures hit rate for a fixed
threshold stimulus, whereas the HFA measures detec-
tion thresholds), overall loss was nevertheless strongly
correlated between the two tests (Fig. 4), and there was
also good concordance between defects at individual
pointwise locations (~84%). Concordance was partic-
ularly high in healthy controls (95%), with relatively
few locations misclassified as defects. In patients,
concordance scores were still reasonable (78%), but
the precise shape and location of the field loss was not
always perfectly preserved, and there was in particular
a tendency for the spatial extent of the vision loss to be
overestimated. This could be due to a number of
factors, including the limited spatiotemporal precision
of the eye-tracker, or imperfect gaze-calibration. We
believe, however, that the current implementation
represents a good compromise between accuracy, cost,
and test duration. For example, even without any
refinement this feasibility study has illustrated that
Eyecatcher can reliably detect moderate visual field
loss, which is important for effective case finding.
In terms of usability, participants rated Eyecatcher
as more enjoyable, easier to perform, and less tiring
than SAP, and found it less hard to concentrate on
than SAP. Participants also reported good task-
comprehension on both tests (though this was to be
expected in the case of SAP, as they all had existing
prior experience of performing the test). These
findings are particularly important and encouraging,
because effective case finding depends on ease-of-use.
The results are also consistent with a recent study by
McTrusty and colleagues,14 which also found eye-
movement perimetry to be more comfortable than
traditional SAP, most likely due to the participant
being able to move their eyes and head during the test.
In terms of test duration, Eyecatcher was faster than
the HFA (5.1 vs. 6.9 minutes). However, the difference
was modest considering the fact that Eyecatcher used a
smaller grid, and used fixed-luminance stimuli (i.e., is a
suprathreshold test, whereas the HFA estimates exact
thresholds). Furthermore, test durations were substan-
tially longer than other proposed screening measures,
such as Frequency Doubling Technology (~1 mi-
nute46,47,51,52). That test durations were not shorter in
part reflects the fact that Eyecatcher required addition-
al time to calibrate the eye-tracker, and also the fact
that each target location was tested multiple times
(four) to compensate for potential eye-tracking error.
However, the relatively long test duration (~5 minutes)
is a limitation of the present test. We are currently
exploring ways to reduce tests times, including im-
proved calibration algorithms, and more efficient
testing algorithms: for example, a single response may
be sufficient if it is consistent with previous responses to
neighboring locations. It is also worth noting that the
intuitive nature of eye-movement perimetry saves time
in a way that is not captured by traditional test duration
metrics. Thus, with SAP, substantial additional time is
required to explain the test and position the patient
appropriately. With Eyecatcher, these requirements are
largely eliminated, potentially allowing for more
substantial time savings overall.
Further work is required to establish decision
boundaries for the present test. Thus, it was
encouraging that, even by casual inspection, there
was a clear difference between healthy and affected
eyes (Fig. 3), with minimal ‘‘false positive’’ red areas
in the healthy controls. In the longer term though, for
a test to be of practical utility there must exist a clear,
formal procedure for mapping any results to the
appropriate clinical decision: in this case, whether or
not to refer the patient for further testing. The most
straightforward way to do this would be to establish a
‘‘traffic light’’ system (mild / moderate / severe loss)
based on normative limits. Alternatively, machine
learning could be used to detect abnormal field-loss
patterns, using the same basic techniques as those
used elsewhere for classifying retinal images.53,54 Of
course, in either case, a much larger sample of
patients will be required.
A potential limitation of the present device is its
restricted spatial range (the majority of stimuli were
presented within 6158 horizontal, and 698 vertical).
In practice, the spatial range appeared sufficient to
reliably discriminate between cases of glaucoma and
age-similar controls, and this is consistent with a
growing body of work indicating substantial central
and paracentral impairments in glaucoma.55,56 It is
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conceivable, however, that individuals with a local-
ized defect in the far periphery might be missed using
the present device. Furthermore, it is important to
note that the test was conducted under laboratory
conditions. It remains an open question how well the
test will perform in real clinical environments where,
for example, one has less control over the ambient
lighting conditions and the presence of potential
distractors. Equally, it is not possible to assess at
present how robust the test is to operator error, and
whether, for example, rigorous training is required to
ensure that the screen and eye-tracker are positioned
correctly (e.g., in order to maintain an appropriate
viewing angle and accurate determination of gaze).
Finally, it is also important to note that the present
study used a self-selecting subset of individuals who
are likely to be relatively compliant and motivated. It
remains to be seen how robust Eyecatcher is when
applied to a larger, more diverse cohort, including, in
particular, individuals who may be highly inattentive
or malingering. It would also be instructive to evaluate
the device with other conditions associated with visual
field loss, such as diabetes, retinal dystrophies, and
neurological disoders.57,58 We are currently investigating
all of these factors by undertaking a more extensive
evaluation of the device in an everyday clinical
environment. We are also encouraged by the fact that
many of these potential concerns can also be addressed
in future by emerging technologies. For example, the
same basic test could be deployed on a VR headset with
an enclosed screen and integrated eye-tracking. This
would allow extremely wide fields of view, complete
control over ambient lighting, and real-time tracking of
head-position, eye-position, gaze, and pupil size—all of
which could be used as potential biomarkers for
attentiveness/compliance.59,60
In terms of potential applications, Eyecatcher is
primarily intended as a rapid, portable case-finding
device, for use in community settings where specialist
equipment/expertise is unavailable. In this respect, the
fact that Eyecatcher is quick, cheap, does not require
any physical contact with the participant, and does
not require any explicit task instructions, makes it
particularly attractive. Its portability and low cost
also makes it well-suited to other situations where
traditional SAP is unaffordable or impractical, for
example for use in home monitoring,20 or in
developing countries. Finally, this work spotlights
the principle of using inexpensive eye tracking
technology to ‘‘automatically’’ assess vision, leading
to examinations that are far less demanding, and
require less co-operation from the person being
examined. Notably, the same basic equipment can
also be used to test other aspects of vision. For
example, by replacing spots of light with gratings of
variable spatial-frequency, acuity can be measured.10
This approach could be particularly useful for
populations who are currently hard to test, such as
children, the very old or infirm, stroke patients, or
individuals with cognitive impairments.
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